A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis

A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis

Summary: Background: In trials conducted in India, recombinant granulocyte colony stimulating factor (GCSF) improved survival in alcohol-associated hepatitis (AH). The aim of this trial was to determine the safety and efficacy of pegfilgrastim, a long-acting recombinant GCSF, in patients with AH in...

Full description

Bibliographic Details
Main Authors: John A. Tayek, Andrew A. Stolz, Danh V. Nguyen, M. Wayne Fleischman, John A. Donovan, Joseph M. Alcorn, Daniel C-K. Chao, Aliya Asghar, Timothy R. Morgan, Divya Birudaraju, Greg Botwin, Hema Buddha, Lavanya Cherukuri, Sheena Cruz, Monique French, Rachel Gonzalez, Jessica Gozum, Rebecca Gutierrez, Sajad Hamal, Preston Head, Carol Jones, Neil Kaplowitz, Robert Lee, Lauren MacHarg, Susan Milstein, Yuxin Ouyang, Christy Rico, Cory Zarick
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:EClinicalMedicine
Subjects:
Alcoholic hepatitis
Pegfilgrastim
Phase II
Randomized clinical trial
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537022004199

Internet

http://www.sciencedirect.com/science/article/pii/S2589537022004199

Similar Items